Literature DB >> 9634042

Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients.

H Wijkström1, U Norming, M Lagerkvist, B Nilsson, I Näslund, P Wiklund.   

Abstract

OBJECTIVE: To evaluate retrospectively the clinical staging in a consecutive series of patients selected for cystectomy and to define its limitations with a view to possible improvements. PATIENTS AND METHODS: From 1979 to 1988, 276 patients with newly detected or recurring transitional cell carcinoma (TCC) of the bladder, were offered pre-operative irradiation (20 Gy) and cystectomy. The patients were assessed during 1995 and the outcome related to both clinical and surgical data. Survival was analysed on the basis of 'intention to treat'. Estimates of survival probabilities were calculated by the method of Kaplan and Meier. Differences in survival among subgroups were assessed using the log rank test and Cox stepwise regression analysis.
RESULTS: Cancer-specific actuarial survival for the whole series was 68% at 5 years and 63% at 10 years. Survival was closely related to the depth of invasion found at surgery, clearly discriminating those with tumours confined to the bladder wall (< or = P3A) from those with extravesical extension (> or = P3B). The cancer-specific survival at 5 years for patients with < or = P3A tumours was 85% and for those with > or = P3B tumours was 50%. This important distinction was anticipated accurately using bimanual palpation before surgery, those patients with no palpable mass after transurethral resection of bladder tumour (TURBT) having an actuarial survival of 83%, and those with a residual mass a survival of 50% at 5 years. In the multivariate analysis, increasing clinical stage was the only pretreatment variable with significant prognostic value for survival. However, this variable was highly dependent on the palpatory findings after TURBT, the presence of a residual mass being a prerequisite for the clinical stage T3 in case of muscle-invasive tumour.
CONCLUSION: Bimanual palpation remains crucially important in clinical staging, and there is a need for further standardization and refinement of this procedure.

Entities:  

Mesh:

Year:  1998        PMID: 9634042     DOI: 10.1046/j.1464-410x.1998.00637.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  12 in total

Review 1.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

2.  Bimanual palpation for staging of bladder cancer-clinical use and its predictors.

Authors:  Lukasz Bialek; Slawomir Poletajew; Piotr Maciej Magusiak; Mikolaj Ostrach; Jakub Szpernalowski; Bartosz Dybowski; Piotr Radziszewski
Journal:  Turk J Urol       Date:  2018-11-21

3.  P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.

Authors:  Wassim Kassouf; Philippe E Spiess; Gordon A Brown; Mark F Munsell; H Barton Grossman; Arlene Siefker-Radtke; Colin P N Dinney; Ashish M Kamat
Journal:  Eur Urol       Date:  2007-04-10       Impact factor: 20.096

4.  Staging error in the bladder tumor: the correlation between stage of TUR and cystectomy.

Authors:  Z Bayraktar; G Gurbuz; A I Taşci; G Sevin
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 5.  Bladder-sparing approaches to invasive disease.

Authors:  Jason A Efstathiou; Anthony L Zietman; Donald S Kaufman; Niall M Heney; John J Coen; William U Shipley
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

6.  Guideline of guidelines: Muscle-invasive bladder cancer.

Authors:  Nicolas Pavlos Omorphos; John Carlo Pansaon Piedad; Nikhil Vasdev
Journal:  Turk J Urol       Date:  2020-09-21

7.  CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma.

Authors:  Yong-kang Ye; Xue-cheng Bi; Hui-chan He; Zhao-dong Han; Qi-shan Dai; Yu-xiang Liang; Guo-hua Zeng; Wei-jun Qin; Zhi-nan Chen; Wei-de Zhong
Journal:  Clin Exp Med       Date:  2010-01-13       Impact factor: 3.984

8.  A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.

Authors:  David J McConkey; Woonyoung Choi; Yu Shen; I-Ling Lee; Sima Porten; Surena F Matin; Ashish M Kamat; Paul Corn; Randall E Millikan; Colin Dinney; Bogdan Czerniak; Arlene O Siefker-Radtke
Journal:  Eur Urol       Date:  2015-09-03       Impact factor: 20.096

Review 9.  The role of a second transurethral resection for high-grade bladder cancer.

Authors:  P Langenstroer; W See
Journal:  Curr Urol Rep       Date:  2000-10       Impact factor: 2.862

Review 10.  Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review.

Authors:  Manouk K Bos; Rafael Ordoñez Marmolejo; Coen R N Rasch; Bradley R Pieters
Journal:  J Contemp Brachytherapy       Date:  2014-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.